ATTOC Intervention for Nicotine Dependence

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Nicotine Dependence+1 More
ATTOC Intervention - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will be conducted in 14 mental health clinics in Philadelphia. The clinics will be assigned at random to either the Addressing Tobacco Through Organizational Change model (ATTOC) or the Usual Care group. The investigators hypothesize that 1) at the end of the intervention and at a 3-month follow-up, rates of adherence to guidelines for treating TUD will be greater among clinic personnel that receive the ATTOC intervention vs. clinic personnel in usual care; 2) at the end of the intervention and at a 3-month follow-up, rates of client smoking cessation will be significantly greater in clinics that receive the ATTOC intervention than

Eligible Conditions
  • Nicotine Dependence

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: Change from baseline to Week 12, Week 24, Week 36, & Week 52

Week 52
Mental health functioning
Short-Form Health Survey
Smoking Knowledge, Attitudes, and Practices (S-KAP)
Smoking Knowledge, Attitudes, and Services (S-KAS)
Week 52
Client hospitalization assessment
Rate of treatment of nicotine dependence - EHR
Rate of treatment of nicotine dependence - Self-report
Treatment and Client Costs
Week 52
Smoking cessation rate

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

ATTOC
1 of 1
Experimental Treatment

832 Total Participants · 1 Treatment Group

Primary Treatment: ATTOC Intervention · No Placebo Group · N/A

ATTOC
Behavioral
Experimental Group · 1 Intervention: ATTOC Intervention · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: change from baseline to week 12, week 24, week 36, & week 52

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
1,816 Previous Clinical Trials
41,114,261 Total Patients Enrolled
19 Trials studying Nicotine Dependence
4,863 Patients Enrolled for Nicotine Dependence
National Cancer Institute (NCI)NIH
12,989 Previous Clinical Trials
41,298,226 Total Patients Enrolled
32 Trials studying Nicotine Dependence
1,650,321 Patients Enrolled for Nicotine Dependence
University of California, San DiegoOTHER
1,011 Previous Clinical Trials
1,792,860 Total Patients Enrolled
2 Trials studying Nicotine Dependence
354 Patients Enrolled for Nicotine Dependence
Robert Schnoll, PhDPrincipal InvestigatorUniversity of Pennsylvania
1 Previous Clinical Trials
80 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must demonstrate the ability to communicate in English and provide written informed consent.
You are 18 years of age or older.
You have a documented mental disorder.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: October 11th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.